Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new ...

Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and ...

A mgen and Kyowa Kirin have announced initial top-line findings from the Phase III ASCEND trial assessing the investigational ...

Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy ...

Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in ...

Across the Phase 3 ROCKET program including ASCEND, the incidence of gastrointestinal ulceration events with rocatinlimab to date is less than 1 per 100 patient-years. The ASCEND study is ongoing and ...

BEDMINSTER, N.J.--(BUSINESS WIRE)--Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ™ (istradefylline) is now available in the U.S. as ...

The FDA recently approved the first drug in a new class of leukemia medicines. Kura Oncology’s endeavor to follow that newly blazed regulatory trail is now infused with $330 million from a ...

Kyowa Kirin is expanding its scope to genetic medicines by acquiring Orchard Therapeutics, a company whose gene therapy for a rare inherited metabolic disorder is commercialized in Europe and is on ...

Following a biopharma industry trend, Kyowa Kirin is narrowing its focus by offloading some mature medicines. The Japanese drugmaker will spin its international established medicines portfolio into a ...

Amgen & Kyowa Kirin announce positive results from rocatinlimab phase 3 ASCEND study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Wednesday, Sept ...